Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Heutsche

Nurse Practitioner, Family Poland, OH Nurse Practitioner

NPI 1265917538 CMS profile 10745025

905 Sahara Trail, Poland, OH 44514

Open in the dashboard

General payments

$5,406

130 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Heutsche of Poland, OH is reported in the CMS Open Payments database as having received $5,406 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $753 35
2024 General $2,292 35
2023 General $232 12
2022 General $2,094 46
2021 General $36 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Heutsche
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Heather Heutsche were reported at $753. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Heather Heutsche Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $36 $124 $35–$379 $132
2022 $2,094 $141 $44–$430 $149
2023 $232 $154 $49–$476 $160
2024 $2,292 $165 $51–$504 $164
2025 $753 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,777 76 payments
  2. Tandem Diabetes Care, Inc. $1,700 5 payments
  3. Insulet Corporation $741 41 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $79 1 payment
  5. Ascensia Diabetes Care US Inc. $32 2 payments
  6. Beta Bionics, Inc. $24 1 payment
  7. Novo Nordisk Inc $16 1 payment
  8. Dexcom, Inc. $14 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $13 1 payment
  10. Lilly USA, LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,892 115 payments
  2. Travel and Lodging $2,502 14 payments
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. t:slim X2 Insulin Pump with Control-IQ $1,700 5 payments
  2. MINIMED 770G $1,515 17 payments
  3. Omnipod $741 41 payments
  4. INPEN SMART INSULIN DELIVERY SYSTEM $739 43 payments
  5. SIMPLERA SENSOR $221 7 payments
  6. MINIMED 780G $156 3 payments
  7. JARDIANCE $79 1 payment
  8. GUARDIAN SENSOR (3) $61 3 payments
  9. MiniMed Connect $50 1 payment
  10. InPen $36 2 payments
  11. Other $194 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

4,547

Median for Nurse Practitioner: 389

Drug cost

$2,251,906

Median for Nurse Practitioner: $21,885

Branded share of claims

77.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 331 $415,600
Ozempic Semaglutide Brand 330 $396,956
Jardiance Empagliflozin Brand 320 $336,198
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 165 $195,158
Mounjaro Tirzepatide Brand 79 $103,376
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 49 $90,220
Humulin R U-500 Insulin Regular, Human Brand 44 $80,261
Humalog Kwikpen U-200 Insulin Lispro Brand 30 $70,317
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 94 $58,523
Tresiba Flextouch U-100 Insulin Degludec Brand 64 $41,817

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$53,084

Medicare's payments for the services billed

Medicare patients

324

Average age 71

Services billed

1,299

173 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 70%
Arthritis 52%
Chronic kidney disease 43%
Ischemic heart disease 32%
Depression 22%
Heart failure 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record